Apogee Therapeutics, Inc. (APGE) Discusses 52-Week Phase 2 APEX Data for Zumilokibart in Moderate to Severe Atopic Dermatitis Transcript
Apogee Therapeutics(US:APGE) Seeking Alpha·2026-03-23 21:33PresentationI will now turn the call over to Noel Kurdi, Vice President of Investor Relations at Apogee. Noel, you may begin.Good morning, and welcome to the Apogee Therapeutics conference call. [Operator Instructions] Please be advised that this call is being recorded at the company's request.Noel KurdiVice President of Investor Relations Thank you, operator, and thank you all for joining us today. During this call, we will be making forward-looking statements related to our current expectations and plans ...